Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status

Oncotarget

Volumn 5, Issue 24, 2014, Pages 12877-12890

  Xiao, Zhiguang ^a   Sperl, Bianca ^a   Ullrich, Axel ^a   Knyazev, Pjotr ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Combinatorial treatment; CSCs; Metformin; NSCLC; Salinomycin

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; PROTEIN KINASE LKB1; PROTEIN KINASE LYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; S6 KINASE; SALINOMYCIN; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; EGFR PROTEIN, HUMAN; EML4 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; PYRAN DERIVATIVE; RAS PROTEIN; SERINE PROTEINASE; STK11 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL DEATH; CELL PROLIFERATION; CELL SHAPE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IC50; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; METFORMIN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASTIC STEM CELLS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRANS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 84921340828     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2657     Document Type: Article

References (36)

1. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremnes RM, Barón AE, Zeng C and Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. Journal of Clinical Oncology. 2003; 21(20):3798-3807.
2. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S and Uematsu K. Frequency of and variables associated with the EGFR mutation and its subtypes. International Journal of Cancer. 2010; 126(3):651-655.
3. Sharma SV, Bell DW, Settleman J and Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer. 2007; 7(3):169-181.
4. Pao W and Girard N. New driver mutations in non-smallcell lung cancer. The lancet oncology. 2011; 12(2):175-180.
5. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T and Perera SA. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007; 448(7155):807-810.
6. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM and Morgan MB. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216):1069-1075.
7. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD. Research Pointers: Metformin and reduced risk of cancer in diabetic patients. BMJ: British Medical Journal. 2005; 330(7503):1304.
8. Dowling RJ, Goodwin PJ and Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC medicine. 2011; 9(1):33.
9. Costa DB and Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes care. 2006; 29(7):1711-1711.
10. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-111.
11. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659.
12. Fuchs D, Daniel V, Sadeghi M, Opelz G and Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochemical and biophysical research communications. 2010; 394(4):1098-1104.
13. Dong T-T, Zhou H-M, Wang L-L, Feng B, Lv B and Zheng M-H. Salinomycin selectively targets 'CD133+'cell subpopulations and decreases malignant traits in colorectal cancer lines. Annals of Surgical Oncology. 2011; 18(6):1797-1804.
14. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research. 2010; 70(2):440-446.
15. Tallarida RJ. Drug synergism: its detection and applications. Journal of Pharmacology and Experimental Therapeutics. 2001; 298(3):865-872.
16. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine. 2005; 352(8):786-792.
17. Pastrana E, Silva-Vargas V and Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell stem cell. 2011; 8(5):486-498.
18. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
19. Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P and Roidl A. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. International Journal of Cancer. 2012; 131(12):2808-2819.
20. Zhang G-N, Liang Y, Zhou L-J, Chen S-P, Chen G, Zhang T-P, Kang T and Zhao Y-P. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer letters. 2011; 313(2):137-144.
21. Liffers S-T, Tilkorn DJ, Stricker I, Junge CG, Al-Benna S, Vogt M, Verdoodt B, Steinau H-U, Tannapfel A and Tischoff I. Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas. BMC cancer. 2013; 13(1):490.
22. Larzabal L, El-Nikhely N, Redrado M, Seeger W, Savai R and Calvo A. Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis. PloS one. 2013; 8(11):e79798.
23. Chen G, Xu S, Renko K and Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. Journal of Clinical Endocrinology & Metabolism. 2012; 97(4):E510-E520.
24. Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti J-F, Le Marchand-Brustel Y and Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-3586.
25. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M and Aritomo Y. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Molecular cancer therapeutics. 2012; 11(3):549-560.
26. Brown KA, Hunger NI, Docanto M and Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast cancer research and treatment. 2010; 123(2):591-596.
27. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac- Dumanovic M, Starcevic V, Micic D and Trajkovic V. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cellular and molecular life sciences. 2007; 64(10):1290-1302.
28. Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS and Yoon S. Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Investigational new drugs. 2012; 30(4):1311-1318.
29. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale C-M, Zhao X and Christensen J. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-1043.
30. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA and Stratton M. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. British journal of cancer. 2004; 91(2):355-358.
31. Li Y, Higashiyama S, Shimakage M, Kawahara K, Yutsudo M and Watari A. Involvement of NANOG Upregulation in Malignant Progression of Human Cells. DNA and cell biology. 2013; 32(3):104-110.
32. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE and Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochemical pharmacology. 2005; 70(6):949-958.
33. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA, Gomez TS, Simeone DM, Bujanda L and Billadeau DD. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis. 2013; 2:e61.
34. Lessard J, Baban S and Sauvageau G. Stage-specific expression of polycomb group genes in human bone marrow cells. Blood. 1998; 91(4):1216-1224.
35. Hindryckx P, De Vos M, Jacques P, Ferdinande L, Peeters H, Olievier K, Brinkman B, Vandenabeele P, Elewaut D and Laukens D. Hydroxylase inhibition abrogates TNF-ainduced intestinal epithelial damage by HIF-1-dependent repression of Fas-associated death domain J Immunol Accepted for publication. Journal of Immunology. 2010:6306-6316.
36. Leung EL-H, Fiscus RR, Tung JW, Tin VP-C, Cheng LC, Sihoe AD-L, Fink LM, Ma Y and Wong MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PloS one. 2010; 5(11):e14062.